Table 1.

Overview of public financial coverage of oral, intravenous (IV) cancer drugs and supportive care drugs by province, territory and federal insurance formularies. For supportive care drugs, we specifically looked at coverage for Neurokinin-1-receptor antagonists and pegfilgrastim. Jurisdictions may have different drugs on public formulary [24,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40].

Jurisdiction	Oral Cancer Drugs	IV Cancer Drug	Supportive Care Drugs
Alberta	Covered, if on formulary	Covered, if on formulary	Not covered
British Colombia	Covered, if on formulary	Covered, if on formulary	Not covered
Manitoba	Covered, if on formulary	Covered, if on formulary	Exception Status
New Brunswick	Exception Status	Covered, if on formulary	Covered, if on formulary
Newfoundland and Labrador	Exception Status	Covered, if on formulary	Exception Status
Nova Scotia	Exception Status	Covered, if on formulary	Exception Status
Prince Edward Island	Limited coverage	Covered, if on formulary	Limited coverage
Ontario	Exception Status	Covered, if on formulary	Exception status
Saskatchewan	Covered, if on formulary	Covered, if on formulary	Covered, if on formulary
Quebec	Exception Status	Covered, if on formulary	Exception Status
Yukon	Exception Status	Covered, if on formulary	Exception Status
Non-insured Health Benefits, Northwest Territories Extended Health Benefits	Exception Status	Covered, if on formulary	Exception status

Green: For patients meeting drug indications, full public drug coverage is provided. Orange: Public drug coverage requires a patient to meet drug indications and an application for exception status. Blue: Public formulary provides full coverage for select medications. Red: Public coverage not offered.